

**20th Oncology Updates: Advances and Controversies**

**1/12/2024 7:00:00 AM - 1/15/2024 10:00:00 AM**

**Target Audience:**

Professions: Physician (MD or DO), Physician Assistant, Other, Nurse - APRN

**Description:**

The treatment of solid tumors continues to evolve and clinicians must stay abreast of the current information and recent therapeutic advances. Many tumor types require multidisciplinary treatment; many therapies previously studied only in advanced and metastatic settings are now applied in early curative stages as well. Healthcare professionals who care for cancer patients in different stages of disease need to understand the basis for these therapies. Additionally, HCPs must apply the preclinical and clinical data supporting the development and integration of these new therapies into their clinical practice. This educational conference will interactively address current management controversies, updates, and novel therapies for multiple tumor types. It will bring together experts from multiple disciplines involved in the treatment of various solid tumors. The expected outcome is the further integration of new cancer care developments into the clinical practice of surgeons, medical oncologists, radiation oncologists, and allied healthcare professionals. This conference is designed to empower these professionals in providing the best possible care for cancer patients.

**Learning Objectives:**

1 Utilize an appropriate sequence for surgical, radiation and chemotherapeutic intervention into the treatment of head and neck cancer, gastrointestinal malignancies, melanoma, lung cancer, breast cancer, gynecologic cancer, and genitourinary cancers.

2 Describe and apply an optimal treatment approach when given patient scenarios representing a range of disease stages, clinical presentations and comorbidities.

3 Incorporate preventive, screening and symptom control modalities in oncology care.

4 Identify patients who will appropriately benefit from novel therapies in the treatment of solid tumors.

5 Utilize the different surgical, radiation, and systemic treatments including immunotherapies and molecular-targeted therapies for cancers at varying stages of disease.

|  |  |
| --- | --- |
|  |  |



**Accreditation:**

|  |  |
| --- | --- |
|  | In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |

**Credit Designation**:

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 19.50 *AMA PRA Category 1* *Credits*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.50 credit(s) of education in medical ethics and/or professional responsibility.

**American Board of Surgery CC Credit:**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for purpose of granting ABS credit.



The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 19.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

**Disclosure of Financial Relationships:**

The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

**Faculty & Planner Disclosure:**

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Eric Gagneaux | Activity Administrator | Nothing to disclose - 07/14/2023 |
| Rodabe N. Amaria, MD | Faculty | Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Grant or research support-Obsidian|Grant or research support-OnKure|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Iovance|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Nektar (Relationship has ended) - 10/31/2023 |
| Brian Badgwell, MD | Faculty | Nothing to disclose - 11/18/2023 |
| Charles M Balch, MD | Faculty | Nothing to disclose - 01/02/2024 |
| Brian K Bednarski, MD | Faculty, Other Planning Committee Member | Nothing to disclose - 09/14/2023 |
| Abigail Caudle, MD, ABS | Faculty | Nothing to disclose - 12/12/2023 |
| Brian F Chapin, MD | Faculty | Advisor-Johnson & Johnson (any division)|Grant or research support-Regeneron Pharmaceuticals, Inc.|Advisor-Merck Research Laboratories and the Office of the Chief Medical Officer Grants|Advisor-Pfizer Inc.|Advisor-Janssen Biotech, Inc. - 12/07/2023 |
| Alyssa C Amin, MPA, PA-C | Other Planning Committee Member | Nothing to disclose - 02/03/2023 |
| Lorenzo Cohen, PhD | Faculty | Nothing to disclose - 08/23/2023 |
| Colin Dinney, MD | Faculty | Consulting Fee-AstraZeneca US|Consulting Fee-CG Oncology|Grant or research support-NHI/NCI|Other: Drug-Nadofaragene firadenovec - 12/06/2023 |
| Steven Frank, MD | Faculty | Consulting Fee-Boston Scientific Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-C4 Imaging|Grant or research support-Hitachi Medical Systems America, Inc.|Grant or research support-Affirmed Pharma|Honoraria-IBA - 12/10/2023 |
| Michael Frumovitz, MD, MPH | Faculty | Consulting Fee-Stryker (any division)|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-AkesoBio|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended) - 12/11/2023 |
| Jeffrey Gershenwald, MD | Faculty | Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Regeneron Pharmaceuticals, Inc. (Relationship has ended) - 09/29/2023 |
| Isabella Glitza Oliva, MD, PhD | Faculty | Consulting Fee-Novartis Pharmaceuticals Corporation|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Pfizer Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division) - 06/30/2023 |
| Wayne Hofstetter, MD | Faculty | Nothing to disclose - 11/10/2023 |
| Kelly K. Hunt, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Armada Health|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Grant or research support-Lilly USA, LLC|Grant or research support-Cairn Surgical|Grant or research support-Lumicell - 11/06/2023 |
| Rosa F Hwang, MD, FACS | Faculty | Grant or research support-Intuitive Surgical, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Stellanova Therapeutics - 12/11/2023 |
| Matthew H Katz, MD | Faculty | Nothing to disclose - 06/13/2023 |
| Paul F Mansfield, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Amgen Inc.|Stocks or stock options, excluding diversified mutual funds-Stryker (any division) - 10/12/2023 |
| Reza Mehran, MD, FACS | Faculty | Nothing to disclose - 09/15/2023 |
| Funda Meric-Bernstam , MD | Faculty | Consulting Fee-AstraZeneca US|Consulting Fee-Biovica (Relationship has ended)|Consulting Fee-Black Diamond (Relationship has ended)|Consulting Fee-Eisai, Inc. (Relationship has ended)|Consulting Fee-F. Hoffmann La Roche (Relationship has ended)|Consulting Fee-Karyopharm Therapeutics (Relationship has ended)|Consulting Fee-Lengo Therapeutics (Relationship has ended)|Consulting Fee-LOXO-Oncology (Relationship has ended)|Consulting Fee-OnCusp Therapeutics (Relationship has ended)|Consulting Fee-Seattle Genetics, Inc.|Consulting Fee-Tallac Therapeutics (Relationship has ended)|Consulting Fee-Zentalis (Relationship has ended)|Consulting Fee-Zymeworks|Grant or research support-Aileron Therapeutics|Grant or research support-AstraZeneca US|Grant or research support-Bayer HealthCare Pharmaceuticals, Inc.|Grant or research support-Calithera|Grant or research support-CytomX Therapeutics|Grant or research support-Curis|Grant or research support-Daiichi Sankyo, Inc.|Grant or research support-Debiopharm|Grant or research support-eFFECTOR Therapeutics|Grant or research support-Genentech, Inc.|Grant or research support-Klus Pharma|Grant or research support-Novartis Pharmaceuticals Corporation|Grant or research support-Puma Pharmaceuticals|Grant or research support-Taiho Oncology, Inc.|Consulting Fee-GT Apeiron (Relationship has ended)|Consulting Fee-Menarini|Consulting Fee-Ecor1|Consulting Fee-Calibr (a division of Scripps Research),|Consulting Fee-LegoChem Bio|Consulting Fee-Theratechnologies|Honoraria-Dava Oncology (Relationship has ended)|Other: Travel Reimbursement-Dava Oncology (Relationship has ended)|Consulting Fee-Protai - 11/06/2023 |
| Neema Navai, MD | Faculty | Royalties or Patent Beneficiary-Allergan, Inc. - 11/29/2023 |
| Timothy Newhook, MD | Faculty | Consulting Fee-Intuitive Surgical, Inc. (Relationship has ended) - 12/08/2023 |
| Quynh-Nhu Nguyen, MD | Faculty | Nothing to disclose - 11/07/2023 |
| Anisha Patel, MD | Faculty | Grant or research support-Pfizer Inc. (Relationship has ended)|Grant or research support-OnQuality|Grant or research support-Lutris|Paid consultant-Deciphera|Paid consultant-Novartis Pharmaceuticals Corporation (Relationship has ended)|Paid consultant-Repare Therapeutics|Paid consultant-Janssen Biotech, Inc.|Grant or research support-Hoth|Paid consultant-Asymmetric|Paid consultant-Lutris - 09/16/2023 |
| Sapna Patel , MD | Faculty | Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Foghorn Therapeutics|Grant or research support-Ideaya|Grant or research support-InxMed|Grant or research support-Lyvgen Biopharma|Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Provectus Biopharmaceuticals|Grant or research support-Seattle Genetics, Inc.|Grant or research support-Syntrix Bio|Grant or research support-TriSalus Life Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Delcath (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Castle Biosciences, Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Ideaya|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-OncoSec (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Replimune (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-TriSalus Life Sciences|Speakers Bureau-Bristol-Myers Squibb Company|Speakers Bureau-Merck Sharp & Dohme Corp. (any division) - 12/11/2023 |
| Peter Pisters, MD | Faculty | Nothing to disclose - 12/22/2023 |
| Victor G Prieto , MD PhD, USCAP, ASDP, ISDP, CAP, ASCP | Faculty | Consulting Fee-Myriad (Relationship has ended)|Consulting Fee-Orlucent|Consulting Fee-Castle Biosciences, Inc. - 12/24/2023 |
| Rae B Reynolds, PhD, APRN | Other Planning Committee Member | Nothing to disclose - 02/16/2023 |
| Merrick I Ross, MD, FACS | Course Director, Faculty | Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Honoraria-Merck Sharp & Dohme Corp. (any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck Sharp & Dohme Corp. (any division) - 09/11/2023 |
| Kathleen M Schmeler, MD | Faculty | Nothing to disclose - 12/29/2023 |
| Stephen G Swisher, MD | Faculty | Nothing to disclose - 12/15/2023 |
| Hop Sanderson Tran Cao, MD, FACS | Faculty | Grant or research support-Intuitive Surgical, Inc.|Grant or research support-Merck Sharp & Dohme Corp. (any division) - 01/01/2024 |
| Ching-Wei D Tzeng, MD | Faculty | Consulting Fee-PanTher|Consulting Fee-Iota - 12/08/2023 |
| Robert A. Wolff, MD, Physician | Faculty | Nothing to disclose - 10/11/2023 |
| Jose Alejandro Rauh-Hain, MD, Associate Professor | Faculty | Consulting Fee-Schlesinger Group|Consulting Fee-Guidepoint - 11/29/2023 |
| Jennifer K. Litton, MD | Faculty | Honoraria-UpToDate|Grant or research support-Pfizer Inc. (Relationship has ended)|Grant or research support-Merck Research Laboratories and the Office of the Chief Medical Officer Grants (Relationship has ended)|Grant or research support-Zenith (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-EMD Serono Inc. (Relationship has ended)|Grant or research support-GlaxoSmithKline (Relationship has ended)|Grant or research support-Genentech, Inc. (Relationship has ended)|Speakers Bureau-Clinical Care Options|Speakers Bureau-Medscape|Speakers Bureau-Physician's Education Resource|Speakers Bureau-Prime Oncology (Relationship has ended)|Speakers Bureau-Medpage|Speakers Bureau-WebMD|Royalties or Patent Beneficiary-Certis|Speakers Bureau-@tumorboardtues (Relationship has ended) - 11/05/2023 |
| Lavinia P Middleton, MD | Faculty | Nothing to disclose - 11/29/2023 |
| Aysegul Sahin, MD | Faculty | Nothing to disclose - 12/12/2023 |
| Ana Ciurea, MD | Faculty | Nothing to disclose - 12/12/2023 |
| Cynthia Scott, BS | Other Planning Committee Member | Nothing to disclose - 09/11/2023 |
| George Perkins, MD | Faculty | Nothing to disclose - 01/02/2024 |
| Justin R. Gregg, MD | Faculty | Advisor-Bayer HealthCare Pharmaceuticals, Inc. - 11/30/2023 |
| Don L Gibbons, MD, PhD | Faculty | Advisor-Lilly USA, LLC (Relationship has ended)|Grant or research support-NGM Biopharmaceuticals (Relationship has ended)|Grant or research support-Boehringer Ingelheim|Advisor-Menarini Ricerche|Advisor-Onconova (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-Sanofi US - 12/12/2023 |
| Ethan B Ludmir, MD | Faculty | Nothing to disclose - 12/26/2023 |
| Mariana C. Chavez MacGregor , MD, MSC, Associate Profesor | Faculty | Grant or research support-Novartis Pharmaceuticals Corporation (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech, Inc.|Advisor-Genomic Health, Inc. (Relationship has ended) - 06/27/2023 |
| Anh Q Dang, MD | Faculty | Nothing to disclose - 12/04/2023 |
| Sumit K Subudhi, MD, PhD | Faculty | Nothing to disclose - 12/10/2023 |
| Jennifer McQuade, MD | Faculty | Honoraria-Merck Sharp & Dohme Corp. (any division) - 12/19/2023 |
| Ana Aparicio, MD | Faculty | Honoraria-Amgen Inc. (Relationship has ended)|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Sanofi US|Honoraria-Astellas Scientific and Medical Affairs, Inc. (Relationship has ended)|Honoraria-Daiichi Sankyo, Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Janssen Biotech, Inc.|Honoraria-AstraZeneca US (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer Inc. - 12/01/2023 |
| Kelly K Bree, MD | Faculty | Nothing to disclose - 12/02/2023 |
| John W Davis, MD, FACS | Faculty | Advisor-Intuitive Surgical, Inc. (Relationship has ended)|Grant or research support-Janssen Biotech, Inc. - 12/28/2023 |
| Roi Weiser, MD | Faculty | Nothing to disclose - 12/03/2023 |
| Matthew T Campbell, MD, MS | Faculty | Advisor-Eisai, Inc. (Relationship has ended)|Advisor-Pfizer Inc. (Relationship has ended)|Consulting Fee-Exelixis (Relationship has ended)|Consulting Fee-Seattle Genetics, Inc. (Relationship has ended)|Grant or research support-Seattle Genetics, Inc.|Advisor-AXDev (Relationship has ended)|Grant or research support-Exelixis|Grant or research support-Pfizer Inc.|Grant or research support-Janssen Biotech, Inc.|Grant or research support-Aravive|Grant or research support-AstraZeneca US|Grant or research support-ApricityHealth (Relationship has ended) - 12/06/2023 |
| Keith Delman, MD | Faculty | Nothing to disclose - 11/30/2023 |
| Maria C Russell, MD | Faculty | Nothing to disclose - 12/11/2023 |
| Thomas Aloia, MD, MPH | Faculty | Nothing to disclose - 10/10/2023 |
| Thomas A Buchholz, MD | Faculty | Nothing to disclose - 12/07/2023 |
| Autumn Atkinson, MD | Faculty | Advisor-Novartis Pharmaceuticals Corporation (Relationship has ended) - 12/11/2023 |
| John Hyngstrom, MD | Faculty | Grant or research support-Amgen Inc.|Grant or research support-Bristol-Myers Squibb Company|Grant or research support-Merck Sharp & Dohme Corp. (any division)|Grant or research support-Lyell|Grant or research support-Natera|Grant or research support-Skyline|Grant or research support-Philogen|Grant or research support-Regeneron Pharmaceuticals, Inc.|Grant or research support-Iovance|Grant or research support-Morphogenesis|Grant or research support-Takara (Relationship has ended) - 12/11/2023 |

**Notice:**

If this activity offers MOC, learner data (e.g., board member ID, first name, last name, DOB, CME credit data) will be shared with the ACCME and the applicable certifying board.

**REQUIREMENTS FOR SUCCESSFUL ACTIVITY COMPLETION:**

To claim CE credits or contact hours for this activity, the participant must:

* **Have a profile in Professional Education Portal (PEP):**
1. Create an account and complete profile in (PEP).
2. Pair your email address to PEP (must use email address used to create PEP account). This is a **one-time** step in order to log your attendance using the text messaging feature in the future. Pairing your phone to the system is done by sending a **text** of your **email address** to **1-844-912-1333.**
* ​**Register** for and attend all sessions of this activity.
* ​**Record Attendance:** During the activity, the learner will TEXT the code: to **1-844-912-1333.** Learners have up to 24 hours after the activity has ended to text this code in order to record attendance.
* **​Evaluation:** Complete the participant evaluation in PEP within 30-days.
* **Claim Credit:** Claim your CE credits. Learners should claim only the credit commensurate with the extent of their participation in the activity.

**REQUIREMENTS TO EARN MOC POINTS (Physicians Only):**

* Complete the above requirements for successful activity completion
* Click the MOC Test button
* Complete your profile information (Specialty Board Diplomate ID and Date of Birth MM/DD)
* Complete the MOC test. A passing score of 70% or higher is required. Unlimited attempts are allowed.

**Commercial Support:**

No commercial support has been received for this activity.